Bruker (NASDAQ:BRKR) Price Target Lowered to $72.00 at TD Cowen

Bruker (NASDAQ:BRKR) had its price target decreased by TD Cowen from $74.00 to $72.00 in a research note published on Wednesday morning, Benzinga reports. TD Cowen currently has a hold rating on the medical research company’s stock.

A number of other brokerages also recently commented on BRKR. StockNews.com downgraded shares of Bruker from a buy rating to a hold rating in a research report on Tuesday, May 21st. The Goldman Sachs Group cut their price target on shares of Bruker from $72.00 to $60.00 and set a sell rating for the company in a report on Tuesday, July 9th. Bank of America dropped their target price on Bruker from $95.00 to $90.00 and set a buy rating on the stock in a research report on Monday, May 20th. Jefferies Financial Group assumed coverage on Bruker in a report on Monday, June 3rd. They issued a buy rating and a $85.00 price target for the company. Finally, Stifel Nicolaus dropped their price objective on Bruker from $81.00 to $77.00 and set a hold rating on the stock in a report on Monday, May 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $80.80.

Bruker Stock Performance

Shares of NASDAQ BRKR traded up $2.53 during trading hours on Wednesday, reaching $62.83. The stock had a trading volume of 350,954 shares, compared to its average volume of 1,027,918. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of 21.93, a PEG ratio of 2.39 and a beta of 1.20. Bruker has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The firm has a 50-day moving average of $64.34 and a 200-day moving average of $75.74. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.52. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The firm had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. During the same quarter last year, the company posted $0.50 earnings per share. The business’s revenue was up 17.4% on a year-over-year basis. Equities research analysts predict that Bruker will post 2.66 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 17th. Stockholders of record on Monday, June 3rd were given a $0.05 dividend. The ex-dividend date was Monday, June 3rd. This represents a $0.20 annualized dividend and a dividend yield of 0.32%. Bruker’s dividend payout ratio is presently 7.27%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. boosted its position in Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares during the last quarter. Lindbrook Capital LLC increased its stake in Bruker by 68.2% in the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 146 shares during the last quarter. Rise Advisors LLC purchased a new position in Bruker during the first quarter worth about $27,000. Neo Ivy Capital Management acquired a new stake in shares of Bruker during the 4th quarter worth $30,000. Finally, GAMMA Investing LLC purchased a new position in shares of Bruker in the 4th quarter worth $33,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.